Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The prognostic impact of t(11;14) in multiple myeloma: A real-world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR).
Lim KJ, Wellard C, Talaulikar D, Tan JL, Loh J, Puvanakumar P, Kuzich JA, Ho M, Murphy M, Zeglinas N, Low MS, Routledge D, Lim AB, Gibbs SD, Quach H, Morgan S, Moore E, Ninkovic S. Lim KJ, et al. Among authors: moore e. EJHaem. 2023 Jul 25;4(3):639-646. doi: 10.1002/jha2.742. eCollection 2023 Aug. EJHaem. 2023. PMID: 37601874 Free PMC article.
Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
Ho PJ, Moore EM, McQuilten ZK, Wellard C, Bergin K, Augustson B, Blacklock H, Harrison SJ, Horvath N, King T, Mollee P, Quach H, Reid C, Rosengarten B, Walker P, Wood EM, Spencer A. Ho PJ, et al. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e415-e424. doi: 10.1016/j.clml.2019.05.010. Epub 2019 May 16. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31208889
The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR).
Bergin K, Wellard C, Moore E, McQuilten Z, Blacklock H, Harrison SJ, Ho PJ, King T, Quach H, Mollee P, Walker P, Wood E, Spencer A; Australian and New Zealand Myeloma and Related Diseases Registry. Bergin K, et al. Among authors: moore e. Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):e510-e520. doi: 10.1016/j.clml.2021.01.016. Epub 2021 Jan 30. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33785297
Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR).
Bergin K, Wellard C, Augustson B, Cooke R, Blacklock H, Harrison SJ, Ho J, King T, Quach H, Mollee P, Walker P, Moore E, McQuilten Z, Wood E, Spencer A; Australian and New Zealand Myeloma and Related Diseases Registry. Bergin K, et al. Among authors: moore e. Bone Marrow Transplant. 2021 Oct;56(10):2533-2543. doi: 10.1038/s41409-021-01308-8. Epub 2021 May 19. Bone Marrow Transplant. 2021. PMID: 34011965
Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction.
Boyle S, Wellard C, Moore EM, Blacklock H, Harrison SJ, Ho PJ, Hocking J, McQuilten ZK, Quach H, Spearing R, Wood EM, Spencer A, Mollee P; Myeloma and Related Diseases Registry investigators. Boyle S, et al. Eur J Haematol. 2021 Oct;107(4):497-499. doi: 10.1111/ejh.13677. Epub 2021 Jun 26. Eur J Haematol. 2021. PMID: 34129711 No abstract available.
Māori and Pacific Peoples With Multiple Myeloma in New Zealand are Younger and Have Inferior Survival Compared to Other Ethnicities: A Study From the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
Moore EM, Blacklock H, Wellard C, Spearing R, Merriman L, Poplar S, George A, Baker B, Chan H, McQuilten ZK, Wood EM, Spencer A; MRDR investigators. Moore EM, et al. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e762-e769. doi: 10.1016/j.clml.2022.04.004. Epub 2022 Apr 8. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35501256
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
McQuilten Z, Wellard C, Moore E, Augustson B, Bergin K, Blacklock H, Harrison S, Ho PJ, King T, Quach H, Mollee P, Rosengarten B, Walker P, Wood E, Spencer A; Australian and New Zealand Myeloma and Related Diseases Registry. McQuilten Z, et al. Among authors: moore e. Br J Haematol. 2022 Sep;198(5):830-837. doi: 10.1111/bjh.18324. Epub 2022 Jul 11. Br J Haematol. 2022. PMID: 35818641 Free PMC article.
The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population.
Tan JLC, Wellard C, Moore EM, Mollee P, Rajagopal R, Quach H, Harrison SJ, McDonald EJ, Ho PJ, Prince HM, Augustson BM, Campbell P, McQuilten ZK, Wood EM, Spencer A; Myeloma and Related Diseases Registry Investigators. Tan JLC, et al. Br J Haematol. 2023 Jan;200(2):e17-e21. doi: 10.1111/bjh.18536. Epub 2022 Nov 2. Br J Haematol. 2023. PMID: 36321478 No abstract available.
4,162 results